Healthcare
Invivyd, Inc.(IVVD)
Live Price
Offline$0.8686
+12.81% today
1Y Change
+32.64%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $200.00M
- Revenue Growth
- +110.5%
- EPS Growth
- +79.0%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Invivyd, Inc. (IVVD) is a Healthcare stock with a market cap of $200.00M and listed on NASDAQ. The stock last traded around $0.87 and up 32.6% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +110.5%, EPS growth of +79.0%, a dividend yield of 0.0%. What stands out right now is revenue +110.5%, EPS +79.0%, free cash flow +65.8% with operating margin -104.0% and ROIC -22.8%. Valuation is more restrained than many high-expectation growth names at price/sales 3.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IVVD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+110.5% vs +7.6% peer median
Operating Margin
Below sector median
-104.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +110.5% and EPS at +79.0%, with operating margin around -104.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.0% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | -0.9% | +2.7% | -17.7% |
2026 Mar 5, 2026 | +133.3% | +3.4% | +3.4% | -26.4% |
2025 Nov 6, 2025 | -20.0% | +2.9% | +14.9% | +44.8% |
Benchmark Edge
IVVD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IVVD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IVVD Max Drawdown
-73.26%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IVVD and SPY.
Company Overview
Invivyd, Inc.
NASDAQ Global Market
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
- Leadership
- William E. Duke Jr.
- IPO Date
- Aug 6, 2021
- Employees
- 99
- Street Address
- 1601 Trapelo Road
- Mailing
- Waltham, MA, 02451
- Region
- Waltham, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 819 0080
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.5
- Price/Sales
- 3.7
- Price/Book
- 1.1
Growth
- Revenue
- +110.5%
- EPS
- +79.0%
- Free Cash Flow
- +65.8%
Profitability
- Gross Margin
- 93.0%
- Operating Margin
- -104.0%
- Net Margin
- -98.2%
- ROE
- -48.7%
- ROIC
- -22.8%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 7.24
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.